转化生长因子α-435G/A基因多态性与非酒精性脂肪性肝病相互关系研究

doi:10.3969/j.issn.1672-5069.2017.01.017

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (1): 65-68.doi: 10.3969/j.issn.1672-5069.2017.01.017

转化生长因子α-435G/A基因多态性与非酒精性脂肪性肝病相互关系研究

邓家征, 申洋, 凌晶, 邓宏, 乐永红, 庄小芳

618000 四川省德阳市人民医院消化内科（邓家征,申洋,凌晶,邓宏,）;
乌鲁木齐市新疆维吾尔自治区中医院肝病科（乐永红,庄小芳）

收稿日期:2015-11-20 出版日期:2017-01-20 发布日期:2017-02-10
作者简介:邓家征,男,43岁,大学本科,副主任医师。研究方向：消化内科常见病诊治研究。E-mail:254528425@qq.com

Transforming growth factor-α-435G/A gene polymorphism in patients with nonalcoholic fatty liver diseases

Deng Jiazheng¹, Shen Yang¹, Ling Jing¹, Deng Hong¹, Le Yonghong², Zhuang Xiaofang²

1 Department of Internal Medicine of Deyang People's Hospital,Deyang 618000,
2 Department of Hepatology,Traditional Chinese Medicine Hospital,Urumqi 830000,Xinjiang Uygur Autonomous Region,China

Received:2015-11-20 Online:2017-01-20 Published:2017-02-10

摘要/Abstract

摘要： 目的研究转化生长因子（TGF）α-435G/A基因多态性与非酒精性脂肪性肝病（NAFLD）发病之间的相互关系。方法选取我院2013年2月至2015年2月收治的NAFLD患者126例作为研究对象,同时以121例正常人作为对照组,采用限制性片段长度多态性（RFLP）分析法对上述研究对象外周血TGFα-435G/A基因进行多态性分析,所获得的数据采用SPSS软件进行分析。结果 NAFLD患者TGFα-435G/A基因型与等位基因的分布与对照组之间并无显著性差异,但是NAFLD患者中AA和GG基因型频率（39.2%和16.3%）和等位基因频率（61.4%和 38.6%）与对照组之间（分别为25.7%和 35.3%,和45.2%和54.8%）存在显著性差异（x²=15.43,P<0.05;x²=16.32,P<0.05）;进一步的研究表明,不同程度NAFLD患者AA、AG、GG基因型频率和等位基因频率也存在一定的差异,即重度脂肪肝患者纯合体（AA和GG）比例相对较高。结论 TGFα-435G/A多肽位点基因突变与NAFLD患者发病之间存在一定的关联性,且不同基因型频率和等位基因频率与病情存在一定的相关性。

关键词: 非酒精性脂肪性肝病, 转化生长因子α, 基因多态性, 基因型, 等位基因

Abstract: Objective To study the transforming growth factor α（TGF-α）-435G/A gene polymorphism in patients with nonalcoholic fatty liver diseases（NAFLD）. Methods 126 patients with NAFLD between February 2013 and February 2015 were recruited in our hospital,and 121 healthy individuals were also included at the same time as control. The polymorphism of TGF-α -435G/A gene in peripheral blood was analyzed by restriction fragment length polymorphism （RFLP） and the data obtained were processed by SPSS software. Results There was no significant difference neither in the TGFα -435G/A genotypes nor the distribution of TGFα-435G/A allele between patients with NAFLD and control（P>0.05）,however,there were significant differences in AA and GG genotype frequency （39.2% vs. 25.7%,and 16.3% vs. 35.3%） and their allele frequency （61.4% vs. 45.2%,and 38.6% vs. 54.8%） between the two groups （x²=15.43,P<0.05;x²=16.32,P<0.05）;And further study showed that patients with NAFLD with different steatosis had different AA GG,AG genotype frequencies and their allele frequencies with relatively high percentage of homozygote（AA,GG） in patients with severe fatty liver diseases. Conclusions There is a certain correlation between the gene mutation of TGFα-435G/A and the incidence of NAFLD,and the frequency of different genotypes and allele might be related to the severity of NAFLD.

Key words: Nonalcoholic fatty liver disease, Transforming growth factor α, Gene polymorphism, Genotype, Allele

邓家征, 申洋, 凌晶, 邓宏, 乐永红, 庄小芳. 转化生长因子α-435G/A基因多态性与非酒精性脂肪性肝病相互关系研究[J]. 实用肝脏病杂志, 2017, 20(1): 65-68.

Deng Jiazheng, Shen Yang, Ling Jing, Deng Hong, Le Yonghong, Zhuang Xiaofang. Transforming growth factor-α-435G/A gene polymorphism in patients with nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 65-68.

参考文献

[1] 闫道普,孙宁. 中西医结合治疗脂肪性肝病的认识与思考.中国新药杂志,2011,20（22）:32-35.
[2] Targher,GF,Marchesini MG. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease:causal effect or epiphenomenon. Diabetologia,2008,51 （11）:1947-1953
[3] Tokushige K,Hashimoto E,Noto H,et al. Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. J Gastroenterol. 2009,44 （9）:976-982.
[4] 智陛雯,赵龙凤,王艳. TGF-β509C/T位点基因多态性与非酒精性脂肪肝病的关系. 中国医疗前沿,2011,1（6）:33-34.
[5] 赖晓波,聂玉强,李瑜元,等. 非酒精性脂肪肝患者瘦素基因G2548A位点多态性与胰岛素抵抗的关系-附107例报告. 新医学,2008,39（12）:781-782.
[6] Yang ZT,Zhang XX,Kong XF,et al. Polymorphisms of microsomal triglyceride transfer protein in different hepatitis B virus-infected patients. World J Gastroenterol. 2008,14（35）:5454-5460.
[7] 叶晓光,廖云珍. 肝病患者血清当中TFGα含量与肝功能的关系研究. 临床肝胆病杂志,2001,17（5）:83-84.
[8] 吕小平,詹灵凌. 慢性肝病患者血清TFG-α和TGF-β的检测及意义. 广州医科大学学报,2002,19（5）:626-627.
[9] Hajiaghamohammadi AA,Ziaee A,Samimi R. The efficacy of licorice root extract in decreasing transaminase activities in non-alcoholic fatty liver disease:A randomized controlled clinical trial. Phytother Res,2012,26（9）:1381-1384.
[10] 倪培华,应雅韵,张洁,等. 肝脂酶启动子250G/A多态性与血脂的关系. 检验学,2005,6（20）:565-567.
[11] Golbidi S,Laher I,Magri CJ. Exercise induced adipokine changes and the metabolic syndrome. J Diabetes Res,2014:726861.
[12] Liu S,Wu HJ,Zhang ZQ,et al. The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. Eur J Pharmacol,2010,650（1）:384-389.
[13] Giby VJ, Ajith TA. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease.World J Hepatol,2014,6（8）:570-579.
[14] Wang C,Yan Y,Hu L,et al. Rapamycin-mediated CD36 translational suppression contributes to alleviation of hepatic steatosis. Biochem Biophy Res Commun,2014,447（1）:57-63.
[15] Soresi M,Noto D,Alberto AB,et al. Nonalcoholic fatty liver and metabolic syndrome in Italy:results from a multicentric study of the Italian Arteriosclerosis society.Acta Diabetologica,2013,（2）:241-249.
[16] 刘益娟. 非酒精性脂肪肝患者发生2型糖尿病危险因素分析及脂肪肝的程度与血糖控制情况的相关性研究.福建医科大学学报,2010,23:142-146.
[17] 朱立红,倪培华,应雅韵,等. 血脂与肝脂酶启动子514C/T多态性的关系. 诊断学理论与实践,2005,4:439.
[18] Anty R,Marjoux S,Tran A. Regular coffee but not express of drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol,2012,57（5）:1090-1096.
[19] Torres DM,Williams CD,Harrison SA. Features,diagnosis,and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol,2012,10（8）:837-858.
[20] Nseir W,Mograbi J,Ghali J. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis:Human studies. Dig Dis Sci,2012,57（7）:1773-1778.
[21] He XP,Xu XW,Zhao SH,et al. Investigation of leptin1 as a candidate gene for fat deposition in pigs. Mol Biol Rep,2009,36（5）:1175-1180.

转化生长因子α-435G/A基因多态性与非酒精性脂肪性肝病相互关系研究

Transforming growth factor-α-435G/A gene polymorphism in patients with nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[3]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[4]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[5]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[6]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[7]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[8]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[9]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[10]	袁春晖,李春雨,李红丽,赵红娜,王文红,孟庆旭,张中学. IL28B基因多态性对聚乙二醇干扰素α治疗HBeAg阳性慢性乙型肝炎患者疗效的影响[J]. 实用肝脏病杂志, 2019, 22(2): 184-187.
[11]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[12]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[13]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[14]	张欢欢, 杨欢, 沈思兰, 陈佳婕, 宣彬彬. 慢性乙型肝炎患者HBV基因型分布及其耐药基因突变分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 41-44.
[15]	赵鹏, 王磊. 聚乙二醇化干扰素-α对不同基因型慢性丙型肝炎患者治疗效果比较^*[J]. 实用肝脏病杂志, 2019, 22(1): 57-60.